Nirmatrelvir-ritonavir use among adults hospitalized with COVID-19 during the Omicron phase of the COVID-19 pandemic, Canadian Nosocomial Infection Surveillance Program
Recent studies have demonstrated the effectiveness of nirmatrelvir-ritonavir in reducing the risk of progression to severe disease among outpatients with mild to moderate coronavirus disease 2019 (COVID-19); however, data are limited regarding the use and role of nirmatrelvir-ritonavir among hospita...
Saved in:
Published in | Canada communicable disease report Vol. 49; no. 7-8; pp. 351 - 357 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Canada
Public Health Agency of Canada
01.08.2023
|
Series | Enteric Diseases: A Major Health Problem in Canada |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Recent studies have demonstrated the effectiveness of nirmatrelvir-ritonavir in reducing the risk of progression to severe disease among outpatients with mild to moderate coronavirus disease 2019 (COVID-19); however, data are limited regarding the use and role of nirmatrelvir-ritonavir among hospitalized patients. This study describes the use and outcomes of nirmatrelvir-ritonavir among adults hospitalized with COVID-19 in a sentinel network of Canadian acute care hospitals during the Omicron variant phase of the pandemic.
The Canadian Nosocomial Infection Surveillance Program conducts surveillance of hospitalized patients with COVID-19 in acute care hospitals across Canada. Demographic, clinical, treatment and 30-day outcome data were collected by chart review by trained infection control professionals using standardized questionnaires.
From January 1 to December 31, 2022, 13% (n=490/3,731) of adult patients (18 years of age and older) hospitalized with COVID-19 in 40 acute care hospitals received nirmatrelvir-ritonavir either at admission or during hospitalization. Most inpatients who received nirmatrelvir-ritonavir, 79% of whom were fully vaccinated, had at least one pre-existing comorbidity (97%) and were of advanced age (median=79 years). Few were admitted to an intensive care unit (2.3%) and among the 490 nirmatrelvir-ritonavir treated inpatients, there were 13 (2.7%) deaths attributable to COVID-19.
These findings from a large sentinel network of Canadian acute-care hospitals suggest that nirmatrelvir-ritonavir is being used to treat adult COVID-19 patients at admission who are at risk of progression to severe disease or those who acquired COVID-19 in hospital. Additional research on the efficacy and indications for nirmatrelvir-ritonavir use in hospitalized patients is warranted to inform future policies and guidelines. |
---|---|
AbstractList | Recent studies have demonstrated the effectiveness of nirmatrelvir-ritonavir in reducing the risk of progression to severe disease among outpatients with mild to moderate coronavirus disease 2019 (COVID-19); however, data are limited regarding the use and role of nirmatrelvir-ritonavir among hospitalized patients. This study describes the use and outcomes of nirmatrelvir-ritonavir among adults hospitalized with COVID-19 in a sentinel network of Canadian acute care hospitals during the Omicron variant phase of the pandemic.
The Canadian Nosocomial Infection Surveillance Program conducts surveillance of hospitalized patients with COVID-19 in acute care hospitals across Canada. Demographic, clinical, treatment and 30-day outcome data were collected by chart review by trained infection control professionals using standardized questionnaires.
From January 1 to December 31, 2022, 13% (n=490/3,731) of adult patients (18 years of age and older) hospitalized with COVID-19 in 40 acute care hospitals received nirmatrelvir-ritonavir either at admission or during hospitalization. Most inpatients who received nirmatrelvir-ritonavir, 79% of whom were fully vaccinated, had at least one pre-existing comorbidity (97%) and were of advanced age (median=79 years). Few were admitted to an intensive care unit (2.3%) and among the 490 nirmatrelvir-ritonavir treated inpatients, there were 13 (2.7%) deaths attributable to COVID-19.
These findings from a large sentinel network of Canadian acute-care hospitals suggest that nirmatrelvir-ritonavir is being used to treat adult COVID-19 patients at admission who are at risk of progression to severe disease or those who acquired COVID-19 in hospital. Additional research on the efficacy and indications for nirmatrelvir-ritonavir use in hospitalized patients is warranted to inform future policies and guidelines. BackgroundRecent studies have demonstrated the effectiveness of nirmatrelvir-ritonavir in reducing the risk of progression to severe disease among outpatients with mild to moderate coronavirus disease 2019 (COVID-19); however, data are limited regarding the use and role of nirmatrelvir-ritonavir among hospitalized patients. This study describes the use and outcomes of nirmatrelvir-ritonavir among adults hospitalized with COVID-19 in a sentinel network of Canadian acute care hospitals during the Omicron variant phase of the pandemic.MethodsThe Canadian Nosocomial Infection Surveillance Program conducts surveillance of hospitalized patients with COVID-19 in acute care hospitals across Canada. Demographic, clinical, treatment and 30-day outcome data were collected by chart review by trained infection control professionals using standardized questionnaires.ResultsFrom January 1 to December 31, 2022, 13% (n=490/3,731) of adult patients (18 years of age and older) hospitalized with COVID-19 in 40 acute care hospitals received nirmatrelvir-ritonavir either at admission or during hospitalization. Most inpatients who received nirmatrelvir-ritonavir, 79% of whom were fully vaccinated, had at least one pre-existing comorbidity (97%) and were of advanced age (median=79 years). Few were admitted to an intensive care unit (2.3%) and among the 490 nirmatrelvir-ritonavir treated inpatients, there were 13 (2.7%) deaths attributable to COVID-19.ConclusionThese findings from a large sentinel network of Canadian acute-care hospitals suggest that nirmatrelvir-ritonavir is being used to treat adult COVID-19 patients at admission who are at risk of progression to severe disease or those who acquired COVID-19 in hospital. Additional research on the efficacy and indications for nirmatrelvir-ritonavir use in hospitalized patients is warranted to inform future policies and guidelines. |
Author | Evans, Gerald Kibsey, Pamela Smith, Stephanie Pelude, Linda Embil, John Minion, Jessica Katz, Kevin Ellis, Chelsey Longtin, Yves Lefebvre, Marie-Astrid Wong, Alice Johnston, Lynn Johnstone, Jennie Frenette, Charles Conly, John Thampi, Nisha Suh, Kathryn Tomlinson, Jen Mitchell, Robyn Lee, Diane Ellison, Jennifer Srigley, Jocelyn Comeau, Jeannette McGeer, Allison Mertz, Dominik Lee, Bonita |
Author_xml | – sequence: 1 givenname: Robyn surname: Mitchell fullname: Mitchell, Robyn organization: Public Health Agency of Canada, Ottawa, ON – sequence: 2 givenname: Diane surname: Lee fullname: Lee, Diane organization: Public Health Agency of Canada, Ottawa, ON – sequence: 3 givenname: Linda surname: Pelude fullname: Pelude, Linda organization: Public Health Agency of Canada, Ottawa, ON – sequence: 4 givenname: Jeannette surname: Comeau fullname: Comeau, Jeannette organization: IWK Health Centre, Halifax, NS – sequence: 5 givenname: John surname: Conly fullname: Conly, John organization: University of Calgary, Calgary, AB – sequence: 6 givenname: Chelsey surname: Ellis fullname: Ellis, Chelsey organization: The Moncton Hospital, Moncton, NB – sequence: 7 givenname: Jennifer surname: Ellison fullname: Ellison, Jennifer organization: Alberta Health Services, Calgary, AB – sequence: 8 givenname: John surname: Embil fullname: Embil, John organization: Health Sciences Centre, Winnipeg, MB – sequence: 9 givenname: Gerald surname: Evans fullname: Evans, Gerald organization: Queen's University, Kingston, ON – sequence: 10 givenname: Lynn surname: Johnston fullname: Johnston, Lynn organization: QEII Health Sciences Centre, Halifax, NS – sequence: 11 givenname: Jennie surname: Johnstone fullname: Johnstone, Jennie organization: Sinai Health, Toronto, ON – sequence: 12 givenname: Kevin surname: Katz fullname: Katz, Kevin organization: North York General Hospital, Toronto, ON – sequence: 13 givenname: Pamela surname: Kibsey fullname: Kibsey, Pamela organization: Royal Jubilee Hospital, Victoria, BC – sequence: 14 givenname: Bonita surname: Lee fullname: Lee, Bonita organization: Stollery Children's Hospital, Edmonton, AB – sequence: 15 givenname: Marie-Astrid surname: Lefebvre fullname: Lefebvre, Marie-Astrid organization: McGill University Health Centre, Montréal, QC – sequence: 16 givenname: Yves surname: Longtin fullname: Longtin, Yves organization: SMBD-Jewish General Hospital, Montréal, QC – sequence: 17 givenname: Allison surname: McGeer fullname: McGeer, Allison organization: Sinai Health, Toronto, ON – sequence: 18 givenname: Dominik surname: Mertz fullname: Mertz, Dominik organization: McMaster University and Hamilton Health Sciences, Hamilton, ON – sequence: 19 givenname: Jessica surname: Minion fullname: Minion, Jessica organization: Saskatchewan Health Authority, Regina, SK – sequence: 20 givenname: Stephanie surname: Smith fullname: Smith, Stephanie organization: University of Alberta Hospital, Edmonton, AB – sequence: 21 givenname: Jocelyn surname: Srigley fullname: Srigley, Jocelyn organization: BC Women's and BC Children's Hospital, Vancouver, BC – sequence: 22 givenname: Kathryn surname: Suh fullname: Suh, Kathryn organization: The Ottawa Hospital, Ottawa, ON – sequence: 23 givenname: Jen surname: Tomlinson fullname: Tomlinson, Jen organization: Health Sciences Centre, Winnipeg, MB – sequence: 24 givenname: Alice surname: Wong fullname: Wong, Alice organization: Royal University Hospital, Saskatoon, SK – sequence: 25 givenname: Nisha surname: Thampi fullname: Thampi, Nisha organization: Children's Hospital of Eastern Ontario, Ottawa, ON – sequence: 26 givenname: Charles surname: Frenette fullname: Frenette, Charles organization: McGill University Health Centre, Montréal, QC |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38455882$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkUuPFCEUhYkZ4zx07c6wdGHNQAEFrIzpcbSTybSJjy25TVFdmCoooaqN84v8mTIPO7riBr577uWcU3QUYnAIvaTknHLJxYW1bTrfc-2lAiKfoBPKFa2UYPSo1FSpitNGH6PTnL8TUjeiYc_QMVNcCKXqE_T7xqcR5uSGvU9V8nMMUCq8ZIdhjGGHoV2GOeM-5snPMPhb1-Kffu7xavNtfVlRjdsl-QLOvcOb0dsUA556KAKxu788gBOE1hXiDV5BgNZDwDcxRxtHDwNeh87Z2Zfuz0vaOz8MEKzDn1LcJRifo6cdDNm9eDzP0Ner919WH6vrzYf16t11ZalmsgINHdUNZ0o2itWSya0mljnCpdtaoRtQhFnVqaZpoW7AFrtqpUUnONlyDewMvX3QnZbt6FrrwpxgMFPyI6RfJoI3_78E35td3BtKNJWcyqLw-lEhxR-Ly7MZfbbu7jsuLtnUWnApmZCsoBcPaDEt5-S6wxxKzH3A5i5gcwi4dLz6d70D_zdR9gcXV6dX |
ContentType | Journal Article |
Copyright | 2023 Public Health Agency of Canada |
Copyright_xml | – notice: 2023 Public Health Agency of Canada |
DBID | NPM AAYXX CITATION 7X8 5PM |
DOI | 10.14745/ccdr.v49i78a07 |
DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Public Health |
EISSN | 1481-8531 |
EndPage | 357 |
ExternalDocumentID | 10_14745_ccdr_v49i78a07 38455882 |
Genre | Journal Article |
GroupedDBID | 29B 2WC 3V. 53G 5GY 6PF 7RV 7X7 7XC 8C1 8FE 8FH 8FQ AAWTL ADBBV AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS ATCPS BENPR BHPHI BKEYQ BPHCQ BVXVI E3Z EBS EJD F5P FRP FYUFA GROUPED_DOAJ HCIFZ HYE M1P M3G NAPCQ NPM OK1 P6G PATMY PKX PQQKQ PROAC PSQYO PYCSY RPM UKHRP W2D AAYXX ABUWG CITATION DWQXO 7X8 5PM |
ID | FETCH-LOGICAL-c1937-a9af19643876832737b90c3e047ebc596a803c8f866da26ac4812895f540b49a3 |
IEDL.DBID | RPM |
ISSN | 1188-4169 1481-8531 |
IngestDate | Tue Sep 17 21:29:18 EDT 2024 Fri Aug 16 09:07:53 EDT 2024 Fri Aug 23 01:03:35 EDT 2024 Tue Oct 15 08:45:55 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7-8 |
Keywords | COVID-19 hospitalized patients nirmatrelvir-ritonavir Omicron |
Language | English |
License | This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY) 4.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c1937-a9af19643876832737b90c3e047ebc596a803c8f866da26ac4812895f540b49a3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Authors’ statement DL and RM analyzed the data. RM drafted the original manuscript. NT and CF contributed equally and are considered co-supervisors of this work. All authors contributed to the conception of this work and acquisition of the data. All authors contributed to the interpretation of the data and review of the manuscript. |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10917417/ |
PMID | 38455882 |
PQID | 2954773573 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10917417 proquest_miscellaneous_2954773573 crossref_primary_10_14745_ccdr_v49i78a07 pubmed_primary_38455882 |
PublicationCentury | 2000 |
PublicationDate | 20230801 |
PublicationDateYYYYMMDD | 2023-08-01 |
PublicationDate_xml | – month: 8 year: 2023 text: 20230801 day: 1 |
PublicationDecade | 2020 |
PublicationPlace | Canada |
PublicationPlace_xml | – name: Canada |
PublicationSeriesTitle | Enteric Diseases: A Major Health Problem in Canada |
PublicationTitle | Canada communicable disease report |
PublicationTitleAlternate | Can Commun Dis Rep |
PublicationYear | 2023 |
Publisher | Public Health Agency of Canada |
Publisher_xml | – name: Public Health Agency of Canada |
SSID | ssj0026563 |
Score | 2.2818859 |
Snippet | Recent studies have demonstrated the effectiveness of nirmatrelvir-ritonavir in reducing the risk of progression to severe disease among outpatients with mild... BackgroundRecent studies have demonstrated the effectiveness of nirmatrelvir-ritonavir in reducing the risk of progression to severe disease among outpatients... |
SourceID | pubmedcentral proquest crossref pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 351 |
SubjectTerms | Surveillance |
Title | Nirmatrelvir-ritonavir use among adults hospitalized with COVID-19 during the Omicron phase of the COVID-19 pandemic, Canadian Nosocomial Infection Surveillance Program |
URI | https://www.ncbi.nlm.nih.gov/pubmed/38455882 https://search.proquest.com/docview/2954773573 https://pubmed.ncbi.nlm.nih.gov/PMC10917417 |
Volume | 49 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT9wwELWAU6WqKv1cCmgqceih2Q2xE9tHtBRBJRYkoOIW2Y6jjcQmqyy7B34RP5Oxnayg3LhFyTiK9Mbxm_HzDCEH1pRSIe4R17GOmC1EpJPE5eAlFQnnJQ8C2Ul2esP-3qa3GyTrz8J40b7R1bC-mw3rauq1lfOZGfU6sdHl-dgVs8SVkI82ySantI_RuzALGYqX1R-iDyDdkF1BH8ZZOjKmaIcrJisulOsg-3wtekUw_9dJPlt4Tj6SDx1jhKPwZdtkw9afyPuQboNwiugzeZxUjnu29m5VtREG_Eiw8QqWCwu-nxD4QhsLmHZ9QqoHW4BLwsL44t_ZcXQoIZxYBGSEcDFzOr0a5lNc5KAp_c214dwlntHiN_S1DWDSIMrNDJ0Zzjp5Vw1Xy3ZlXVcjdCy4DEKwL-Tm5M_1-DTqmjBEBrkdj5RUpS_ahb9NnP2cci1jQ23MuNUmlZkSMTWiFFlWqCRThiFlEDItkQpqJhX9SrbqprbfCRTuIDC3Vku0KssYh7NCyCJWIqEptQPyq4cjn4daG7mLURxyuUMuXyM3ID97uHKcD26TQ9W2WS5yt2_JOU05HZBvAb71y6hgaYohxYCIF8CuDVyt7ZdP0AV9ze3e5XbePvQHeed61Qf14C7Zum-Xdg8Zzb3e95mAfe_GT_QW-vY |
link.rule.ids | 230,315,733,786,790,870,891,27955,27956,53825,53827 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtQwFLVKWYCEeBeG50ViwYJk0tiJ7SUaqGagnVaihe4i23E0EZ1klHks-kV8JtdxMmrLCnZRch0l8rF9bB-fS8h7awqpsN4DriMdMJuLQMexW4OXVMScF9wLZKfp-Ix9PU_Od0jan4VpRftGl2F1MQ-rctZqKxdzM-x1YsOTo5Ezs8SRkA9vkdvYYOOkn6V3Ey3kKK2wfh9RgIRDdpY-jLNkaEzehBsmSy6UyyF7dTT6i2LeVEpeGXoOHpCf_Ud7xcmvcL3Sobm84ef473_1kNzv2Ch88s8fkR1bPSb3_FIe-BNKT8jvael4bWMvNmUTNNgFVAqvYL200OYqgtbEYwmzLgdJeWlzcAu8MDr-Mfkc7EvwpyEB2SYcz50GsILFDAdQqIv25jZw4Ra1MeIj9L4JMK0RQfUcGwpMOulYBd_Xzca6jEkIWjjxIrOn5Ozgy-loHHQJHgKDvJEHSqqiNQTDLhl7Fk65lpGhNmLcapPIVImIGlGINM1VnCrDkI4ImRRIMzWTiu6R3aqu7HMCuTtkzK3VEqOKIsLiLBcyj5SIaULtgHzoKzpbeB-PzM1_HCYyh4lsi4kBedcDIcO25jZQVGXr9TJze6Kc04TTAXnmgbF9GRUsSXC6MiDiGmS2Ac7H-_oTBELr591X_Iv_L_qW3BmfHh1mh5Ppt5fkboxMzKsUX5HdVbO2r5E5rfSbtpn8AfQkHDU |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LatwwFBVtCqVQ0nczfarQRRf1I5ZsScsy6ZDpYzLQpgS6MJIsM6YZ2Xgei3xRP7NXlj0k6S47Y18ZGx1JR9LRuQi9N7oUEuo9YCpWATUFD1SSuDV4QXjCWMm8QHaWHZ_SL2fpWa-qXPWySqtVFdrzZWirRaetbJY6GnRi0fz72JlZwkjIoqYoo9voTupeO8zU-8kW8JROXH8ISADSIXpbH8poGmldtOGWiopx6fLIXh6R_qOZ19WSl4afyQP0e_hwrzr5E27WKtQX1zwdb_ZnD9F-z0rxJx_zCN0y9jG675f0sD-p9AT9nVWO37bmfFu1QQtdgZVwhTcrg7ucRbgz81jhRZ-LpLowBXYLvXh88mt6FBwK7E9FYmCd-GTptIAWNwsYSHFddjd3gY1b3IaIj3jwT8CzGpBUL6HB4GkvIbP4x6bdGpc5CcCL515s9hSdTj7_HB8HfaKHQAN_ZIEUsuyMwaBrhh6GEaZErImJKTNKpyKTPCaalzzLCplkUlOgJVykJdBNRYUkz9Cera05QLhwh42ZMUpAVFnGUJwWXBSx5AlJiRmhD0Nl543388jdPMjhIne4yHe4GKF3AxhyaHNuI0VaU29WudsbZYykjIzQcw-O3csIp2kK05YR4ldgswtwft5XnwAYOl_vofJf3LzoW3R3fjTJv01nX1-iewkQMi9WfIX21u3GvAYCtVZvupbyD72LHrU |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Nirmatrelvir-ritonavir+use+among+adults+hospitalized+with+COVID-19+during+the+Omicron+phase+of+the+COVID-19+pandemic%2C+Canadian+Nosocomial+Infection+Surveillance+Program&rft.jtitle=Canada+communicable+disease+report&rft.au=Mitchell%2C+Robyn&rft.au=Lee%2C+Diane&rft.au=Pelude%2C+Linda&rft.au=Comeau%2C+Jeannette&rft.series=Enteric+Diseases%3A+A+Major+Health+Problem+in+Canada&rft.date=2023-08-01&rft.pub=Public+Health+Agency+of+Canada&rft.issn=1188-4169&rft.eissn=1481-8531&rft.volume=49&rft.issue=7-8&rft.spage=351&rft.epage=357&rft_id=info:doi/10.14745%2Fccdr.v49i78a07&rft.externalDBID=PMC10917417 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1188-4169&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1188-4169&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1188-4169&client=summon |